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n-Myc-induced metabolic 
rewiring creates novel therapeutic 
vulnerabilities in neuroblastoma
Britta tjaden1,8, Katharina Baum  2,8, Viktoria Marquardt3, Mareike Simon2, Marija trajkovic-
Arsic4, Theresa Kouril5, Bettina Siebers  5, Jan Lisec6, Jens T. Siveke  4, Johannes H. Schulte7, 
Uwe Benary  2, Marc Remke3, Jana Wolf2 & Alexander Schramm  1 ✉
n-Myc is a transcription factor that is aberrantly expressed in many tumor types and is often correlated 
with poor patient prognosis. Recently, several lines of evidence pointed to the fact that oncogenic 
activation of Myc family proteins is concomitant with reprogramming of tumor cells to cope with an 
enhanced need for metabolites during cell growth. These adaptions are driven by the ability of Myc 
proteins to act as transcriptional amplifiers in a tissue-of-origin specific manner. Here, we describe 
the effects of N-Myc overexpression on metabolic reprogramming in neuroblastoma cells. Ectopic 
expression of n-Myc induced a glycolytic switch that was concomitant with enhanced sensitivity 
towards 2-deoxyglucose, an inhibitor of glycolysis. Moreover, global metabolic profiling revealed 
extensive alterations in the cellular metabolome resulting from overexpression of N-Myc. Limited 
supply with either of the two main carbon sources, glucose or glutamine, resulted in distinct shifts 
in steady-state metabolite levels and significant changes in glutathione metabolism. Interestingly, 
interference with glutamine-glutamate conversion preferentially blocked proliferation of N-Myc 
overexpressing cells, when glutamine levels were reduced. Thus, our study uncovered N-Myc induction 
and nutrient levels as important metabolic master switches in neuroblastoma cells and identified critical 
nodes that restrict tumor cell proliferation.
Myc proteins are encoded by a small family of proto-oncogenes consisting of MYC, MYCN and MYCL. In nor-
mal tissues, their expression is tightly regulated, while deregulation of MYC family members has been identified 
as a driving force in different cancer types. Since specific binding motifs, termed E-boxes, had been identified 
early on, Myc proteins were considered to be gene-specific transcription factors. This concept has been recently 
extended by different studies suggesting that deregulated Myc in tumors functions as a general transcriptional 
amplifier1–3. However, Myc-induced and tumor-specific mechanisms of target gene control on transcriptional 
level have only recently been addressed mechanistically4. The picture emerges that, at least in settings with vastly 
elevated Myc-levels, enhancer invasion by N-Myc and associated proteins contributes to tumor-specific N-Myc 
signatures. Moreover, the concept of Myc-mediated cell autonomous effects to boost tumor cell proliferation has 
been extended to include restriction of host immune reactions towards a tumor5. Although these efforts led to 
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a better understanding of cell autonomous and cell non-autonomous regulatory circuits governed by oncogenic 
N-Myc functions, insights into mechanistic effects on the level of metabolic circuits is still largely lacking.
Deregulated Myc activity comes along with enhanced metabolic stress and increased sensitivity towards apop-
tosis due to a dependency on continuous supply with nutrients. Glutamine has been identified as a limiting factor 
for Myc-dependent cell growth and glutamine deprivation was preferentially inducing apoptosis in Myc-high 
cells6. In neuroblastoma, the most common solid tumor of childhood, elevated N-Myc levels are often found due 
to amplification of the coding gene, MYCN, which is correlated with poor overall survival of affected patients. 
N-Myc overexpression in the absence of MYCN amplification is not prognostic, pointing to the importance of 
additional genetic factors such as telomerase maintenance for determining disease outcome7. However, forced 
expression of N-Myc is sufficient to induce neuroblastoma in different model organisms including mice8,9 and 
zebrafish10,11 indicating a causative role for N-Myc expression in disease onset and maintenance. Ectopic N-Myc 
expression in neuroblastoma cells is accompanied with increased aggressiveness, but also a higher sensitivity 
towards drug-induced apoptosis in vivo and in vitro12,13. Interestingly, glutamine deprivation was reported to pref-
erentially sensitize MYCN-amplified cells towards programmed cell death14. N-Myc also promoted expression of 
genes involved in glycolysis including lactate dehydrogenase (LDH) and hexokinase 2 (HK2) in neuroblastoma 
in vitro15 and in vivo16. The notion that depletion of LDHA inhibited MYCN-dependent tumorigenesis17 and that 
N-Myc cooperated with HIF1α15 suggested that N-Myc expression could also contribute to the Warburg effect. 
Thus, tumor-specific Myc deregulation directly affects tumor metabolism in multiple pathways.
At present, it is not clear how metabolic dependencies of tumors can be best exploited for therapeutic pur-
poses. It is evident that metabolic features are remarkably flexible, especially those driven by Myc proteins. 
Moreover, tumor-type specific metabolic adaptations have been identified in Myc-driven tumors, exemplified by 
the Myc-mediated de novo synthesis of glutamine18. By contrast, Myc-driven liver tumors rather consume glu-
tamine by a process termed glutaminolysis, which allows for fueling into the tricarboxylic acid cycle (TCA cycle) 
at the level of α-ketoglutarate by activation of glutaminase, another Myc-target19. MYCN-driven glutaminolysis 
has been recently suggested as a strategy to treat Myc-driven cancers20. Still, tumor cell-intrinsic response patterns 
as a consequence of MYCN activation under varying nutrient conditions largely remain to be identified. We thus 
set out to profile metabolic shifts in neuroblastoma cell lines with inducible N-Myc expression and correlate their 
phenotypic responses upon variations in the two most common carbon sources, glucose and glutamine.
Materials and methods
Cell culture and reagents. Neuroblastoma cell lines SHEP, SH-SY5Y, SK-N-AS and SK-N-SH were culti-
vated in RPMI1640 medium containing 10% fetal bovine serum (FBS) and antibiotics as described21–23. Protocols 
for generating inducible expression of a gene of interest have been described before24. In brief, cell lines were 
sequentially transfected with pcDNA6/TR, harboring the tetracycline repressor gene, and pT-REx-DEST30 
(ThermoFisher/ Invitrogen) containing MYCN cDNA. Single cell clones were selected by limiting dilution in 
medium containing blasticidine and G418 (ThermoFisher/ Invitrogen). For all cell lines transfected to express 
N-Myc upon addition of tetracycline, the suffix “TR-MYCN” was added to distinguish them from the paren-
tal cells. N-Myc induction was realized by adding 1 μg tetracycline per ml medium. Cell lines were authenti-
cated by STR genotyping prior and post transfections. All reagents used for cell culture were obtained from 
Gibco/ ThermoFisher. Absence of Mycoplasma sp. in cultivated cells was confirmed by performing PCR with 
Mycoplasma-specific primers (IDT).
Metabolic activity, cell viability and cell proliferation assays. Metabolic activity was assessed using 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay for cells at the onset or in loga-
rithmic growth phase. For monitoring cell viability upon inhibition of glutamine metabolism, automated cell han-
dling in a 384 well format was used. Cell Titer Glo assays were performed using a Spark 10 M microplate reader 
(Tecan) as described25. For monitoring cell proliferation, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was performed as described26.
Protein analyses and antibodies. Either whole-cell protein extracts or fractionated cell extracts were 
separated by SDS-PAGE (10%) and subsequently used for western blotting. Immunoblot analysis was performed 
using primary antibodies targeting hexokinase II (1:500 dilution; #2106); hexokinase I (1:1000; #2804); N-Myc 
(1:1000; #9405); c-Myc (1:1000; #9402); PHGDH (1:1000, #13428, all from Cell Signaling Technology). To 
ensure equivalent protein loading, blots were stained with a primary antibody raised against β-actin (1:2000 
dilution; #A5441, Sigma Aldrich Merck, Munich, Germany). Detection and visualization was achieved using 
HRP-conjugated goat anti-mouse or anti-rabbit secondary antibodies (GE Healthcare) and the ECL™ Prime 
Western Blotting Detection Reagent (GE Healthcare, #RPN2236), respectively. Data were analyzed using a 
FusionFX7 detection device (Vilber Lourmat).
Real-time reverse transcriptase-PCR. Total RNA was isolated from cells using the High Pure RNA 
Isolation Kit (Roche, #11828665001), and cDNA synthesis was performed using the Transcriptor First Strand 
cDNA Synthesis Kit (Roche, #04379012001). Expression of target genes was monitored using a StepOnePlus™ 
Real-Time PCR System (Applied Biosystems) and Fast SYBR® Green Master Mix (Roche, #04913914001). 
Expression values were normalized to β-actin expression and the fold change was calculated using the ΔΔ − Ct 
method.
Glycolysis flux assays. Glycolysis flux assays were performed in a Seahorse 96-well XF Cell Culture 
Microplate using a XF96 sensor cartridge according to the manufacturer’s instructions (Seahorse Bioscience, 
#102416-100). Briefly, 20,000 cells per well were allowed to grow overnight in a 37 °C, 5% CO2 incubator in 
pyruvate-free RPMI1640 (Gibco/ThermoFisher Scientific, #21875-034, #31870-025, #11879-020) with 
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L-glutamine (Gibco/ThermoFisher Scientific, #25030-024) and varying concentrations of D-glucose (Gibco/
ThermoFisher Scientific, #A2494001), 10% fetal bovine serum (Gibco/ThermoFisher Scientific #10270-106) and 
antibiotics. On the next day, medium was replaced with pyruvate- and glucose-free Seahorse XF Base Medium 
(#102353-100) supplemented with 2 mM glutamine according to the manufacturer’s protocol. The microplates 
were incubated at 37 °C for 45 min and then transferred to the microplate stage of a Seahorse XFe96 Extracellular 
Flux Analyzer to quantify the extracellular acidification rate (ECAR, in [mpH/min]) and the oxygen consumption 
rate (OCR, in [pmol/min]) using glucose concentrations as indicated. For each step, three separate ECAR and 
OCR readings using a mix and measure cycling protocol (3 min each) were recorded. Data for each experimental 
condition were calculated from a minimum of 10 technical replicates.
Metabolic profiling. SHEP-TR-MYCN cells with and without induction of MYCN were incubated under 
varying glucose or glutamine concentrations. Upon harvesting, samples were prepared using the automated 
MicroLab STAR® system (Hamilton). To recover chemically diverse metabolites, proteins were precipitated with 
methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The 
resulting extract was analyzed either by separate reverse phase (RP)/UPLC-MS/MS with positive ion mode elec-
trospray ionization (ESI), RP/UPLC-MS/MS with negative ion mode ESI or HILIC/UPLC-MS/MS with nega-
tive ion mode ESI. The sample extracts were stored overnight under nitrogen before preparation for analysis. 
All methods utilized a Waters ACQUITY ultra-performance liquid chromatography (UPLC) and a Thermo 
Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ioniza-
tion (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. Raw data was extracted, 
peak-identified and QC processed using hardware and software developed by Metabolon Inc..
Statistical analysis. Statistical analyses of metabolic profiling data were performed using R, version 3.3.2 
(available at cran.r-project.org). Prior to analyses, samples were normalized according to protein content deter-
mined by Coomassie G-250 based assays. For detailed procedures see Supplemental Methods. If not indicated 
otherwise, data are presented as mean and standard error of the mean (SEM).
Results
Metabolic reprogramming of SHEP cells depends on carbon source supply and N-Myc expres-
sion. We had previously described a correlation of MYCN with HK2 mRNA expression in SHEP human neu-
roblastoma cells engineered to stably express N-Myc or to activate N-Myc only in the presence of tamoxifen27. 
To better understand the cellular and the metabolic response towards N-Myc induction and varying glucose /
glutamine ratios, we here used SHEP cells with tightly controlled conditional upregulation of N-Myc in the pres-
ence of tetracycline (SHEP-TR-MYCN). Expression analyses confirmed both, N-Myc induction and concomitant 
hexokinase II protein (HKII) upregulation in these cells (Fig. 1A). SHEP-TR-MYCN cells were then cultivated 
with or without N-Myc induction and varying glucose and glutamine levels. Of note, N-Myc and HKII induction 
appeared to be independent of glucose and glutamine concentrations in the medium (Fig. 1A). We defined ten 
experimental groups that differed in N-Myc expression levels and nutrient supply (Table 1) to mimic different 
carbon source availability in the presence or absence of N-Myc. Metabolomic profiling by ultrahigh performance 
liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) identified 499 compounds, of which 495 
(99.2%) were present in at least one third of all samples. Upon normalization to protein content and imputation 
of missing values, principal component analysis (PCA) demonstrated separation of samples according to N-Myc 
expression. PCA also separately grouped samples cultivated at low or high concentrations of glucose or glutamine 
(Fig. 1B). We performed two condition-specific analyses of variance (ANOVAs) for each metabolite, one for con-
stant glutamine conditions to examine the effect of glucose variation, and one for constant glucose conditions to 
examine the effect of glutamine variation. For each condition, we only analyzed metabolites which were present 
in at least one third of samples considered (Table 1). Induction of N-Myc was associated with consistent metabolic 
shifts, as 144/496 (29%, for constant glutamine) or 365/486 (75%, for constant glucose) of the metabolites were 
significantly altered (FDR < 0.05) between N-Myc high and N-Myc low expressing cells (Fig. 1C,D; Supplemental 
Figs. 1 and 2). A comparable number of metabolites were significantly affected when glucose (199/496, 40%) or 
glutamine levels (352/486, 73%) were varied. We then examined a possible interaction effect between N-Myc 
expression levels and glucose or glutamine supply. ANOVAs revealed a significant interaction between varying 
N-Myc expression and glucose concentrations affecting 24% of all metabolites (120/496 metabolites, FDR < 0.05) 
when only samples with constant glutamine concentrations were considered (Fig. 1C). An even higher number of 
metabolites (240/486, FDR < 0.05) had a significant interaction effect between N-Myc and glutamine when ana-
lyzing samples that had constant glucose concentrations (Fig. 1D). Classification of these metabolites according 
to “super pathways”28 was performed to uncover patterns according to metabolic categories. Here, metabolites 
classified in the category “energy metabolism” had the highest relative enrichment (Supplemental Figs. 1 and 2). 
Thus, global profiling suggested tight interaction of N-Myc and carbon source levels in metabolic reprogramming 
of SHEP cells, while HKII was confirmed as a N-Myc target independent of carbon source availability.
N-Myc shifts the balance from oxidative phosphorylation to glycolysis. To examine if 
up-regulation of pacemaker enzymes of glycolysis including HKII were concomitant with a switch in energy 
harvest, we tested different scenarios in SHEP cells with varying N-Myc levels and glucose supply. In all con-
ditions analyzed, we observed a shift towards preferential use of glycolysis upon MYCN induction as seen in 
higher ECAR levels (Fig. 2A). This effect was independent of glucose concentration (Fig. 2A) and cell num-
ber (Fig. 2B). Interestingly, N-Myc-induced upregulation of HKII did not result in altered steady state HK 
enzymatic activity. N-Myc low and N-Myc high cells also had comparable activity of other glycolytic proteins, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), lactate dehydrogenase (LDH), triosephosphate isomerase 
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(TIM) and pyruvate kinase (PK, Supplemental Fig. 3). Of note, we could confirm that c-Myc levels decrease 
upon N-Myc induction (Supplemental Fig. 3). Moreover, subcellular fractionation revealed no difference in 
HK activity for N-Myc low and N-Myc high cells in different cellular compartments (Supplemental Fig. 4). 
While siRNA-mediated knockdown of either HKI or HKII was tolerated regardless of N-Myc expression levels 
(Supplemental Fig. 5), blocking of glycolysis downstream of HK by using 2-deoxyglucose (2-DG) preferentially 
affected SHEP cells with high N-Myc levels (Fig. 2C). To check whether this effect could be recapitulated in other 
neuroblastoma cells, we ectopically expressed inducible N-Myc in three additional human neuroblastoma cell 
lines without MYCN gene amplification, SK-N-AS, SK-N-SH and SY5Y. Again, induction of N-Myc was accom-
panied by upregulation of HKII (Fig. 2D). N-Myc-mediated sensitization towards 2-DG was also observed for 
SK-N-AS cells, while SY5Y cells were intrinsically more sensitive to 2-DG regardless of MYCN expression levels 
(Supplemental Fig. 6). Thus, N-Myc overexpression induced a shift to preferential usage of glycolysis and also 
increased sensitivity towards inhibition of the glycolytic pathway in a cell line specific manner.
N-Myc induces cell-type specific responses upon interference with different steps of glutamine 
biosynthesis. Cellular reprogramming by Myc proteins has been shown to affect glutamine metabolism, 
consistent with an increased demand of tumor cells for glutamine and metabolic adaptions to fluctuations in 
nutrient supply (reviewed in29). As for glucose, we observed a high number of significantly altered metabo-
lites depending on MYCN expression levels when glutamine supply was varied. As indicated above, bifactorial 
ANOVAs revealed that 49% of all metabolites displayed a significant interaction effect between N-Myc induction 
and glutamine levels suggesting that these factors are intricately linked to metabolic reprogramming. As Myc 
proteins upregulate both, the import of glutamine and mitochondrial glutaminolysis, we aimed to investigate the 
cellular response to inhibition of glutamine metabolism upon MYCN induction. Blocking glutamine uptake by 
L-γ-Glutamyl-p-nitroanilide (GPNA) did not affect cell viability regardless of N-Myc expression levels (Fig. 3A). 
Paradoxically, inhibition of glutaminase by a small molecule inhibitor, CB-839, increased relative cell viability in 
SK-N-SH TR-MYCN and SHEP-TR-MYCN cells upon MYCN induction when glutamine supply was limited. 
Figure 1. (A) Western blot analyses of hexokinase II (HKII) and N-Myc expression in SHEP-TR-MYCN 
cells. “+” and “−“ refer to induction of N-Myc expression by tetracycline (Tet). Arrows indicate high or low 
concentration of glucose and glutamine, respectively. Double arrows indicate concentrations of both carbon 
sources used for normal cell culture (cf. Table 1). (B) Principal component analysis (PCA) of metabolic profiling 
data using SHEP-TR-MYCN cells. In total, 495 metabolites present in at least 10 measurements were included. 
Each symbol denotes one sample. Blue symbols indicate conditions without N-Myc induction (“MYCN low”), 
while red symbols refer to samples with high N-Myc expression upon induction by Tet (“MYCN high”). 
Low and high levels of glucose and glutamine, respectively, were used as defined in Table 1. (C) Numbers of 
metabolites significantly affected by N-Myc, glucose abundance or with significant interaction effect according 
to bifactorial ANOVAs using sample groups with constant glutamine conditions and varying glucose levels (cf. 
Table 1). (D) Numbers of metabolites significantly affected by N-Myc, glutamine abundance or with significant 
interaction effect according to bifactorial ANOVAs using the sample groups with constant glucose conditions 
and varying glutamine levels (cf. Table 1).
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However, CB-839 did not affect viability of SY5Y TR-MYCN and SK-N-AS TR-MYCN cells over a wide concen-
tration range regardless of N-Myc and glutamine levels, while cell proliferation was reduced at high concentra-
tions of CB-839 (Fig. 3B,C and Supplemental Fig. 7). Induction of MYCN highly sensitized SY5Y TR-MYCN and 
SK-N-AS TR-MYCN cells to low doses of the amino acid analogue DON (6-diazo-5-oxo-L-norleucine), which 
inhibits the conversion of glutamine to glutamate. Cell proliferation, but not cell viability of SHEP-TR-MYCN was 
affected by DON at concentration >10 µM, while cell viability of SK-N-SH TR-MYCN upon MYCN induction 
in the presence of DON was only reduced under low glutamine conditions (Fig. 3D,E and Supplemental Figs. 7 
and 8). Blocking the link between glutaminolysis and the TCA cycle by inhibiting the conversion of glutamate 
to α-ketoglutarate using aminoxyacetate (AOA) did not affect either of the cell lines regardless of N-Myc or 
glutamine levels (shown exemplarily for SHEP-TR-MYCN in Fig. 3F). Thus, intervention with glutamine metab-
olism in neuroblastoma cells uncovered cell-type specific adaptations and metabolic dependencies modulated by 
MYCN expression and glutamine levels.
N-Myc affects the entire pathway of glutathione biosynthesis, but exogenous glutathione does 
not restore viability of N-Myc high cells. In our analysis of metabolome data, classification of known 
metabolites according to “super pathways”28 was also performed to uncover MYCN-induced patterns according 
to metabolic categories under varying glutamine concentrations. Significant overrepresentation of metabolites 
upon MYCN induction under these conditions was observed only for the group of “peptides” (Supplemental 
Fig. 9). Here, 26/26 di-peptides were significantly altered when cells with different N-Myc levels were compared. 
Detailed analyses of this group revealed that 12 of the di-peptides contained gamma-glutamyl residues and 
were linked to glutathione metabolism. Additional metabolites annotated as members of “glutathione metab-
olism”30 were also significantly altered by N-Myc levels independent of glutamine supply (32/34 metabolites, 
Fig. 4A); glutathione-associated metabolites were significantly over-represented among the MYCN-affected 
metabolites (p-value 0.003, Fisher’s exact test). Strikingly, almost all metabolites involved in glutathione metab-
olism, including glutamine, were found at significantly lower levels in N-Myc high cells compared to N-Myc low 
cells regardless of glutamine supply (Fig. 4B). While this suggested a limiting role of glutathione availability for 
N-Myc high cells, DON-mediated reduced viability of SHEP-TR-MYCN cells could not be rescued by exoge-
nous glutathione supply (Fig. 4C). Additionally, increasing reactive oxygen species (ROS) by mono- or dimethyl 
fumarate (MMF, DMF) did also not affect cell viability upon MYCN induction and varying glutamine supply 
(Fig. 4D, Supplemental Fig. 10). These results indicate that MYCN induction causes a significant depletion of 
glutamine-related metabolites including glutathione, and that the resulting glutamine addiction cannot be attrib-
uted to modulation of ROS levels.
Discussion
The wealth of data on plasticity of tumor cells suggests that blocking of single metabolic pathways may not be 
sufficient for long-term control of cancer growth. However, it is crucial to analyze oncogene-induced adapta-
tions of metabolic pathways on a cellular level to understand mechanisms of metabolic plasticity contributing to 
development of therapy resistance in cancer. Still, tumor cell-centric assays are limited as they will miss interac-
tions with the tumor microenvironment. A prime example is the notion that KRAS driven lung tumor cells are 
Group Cell line Description
Gluc 
[g/L]
Gln 
[mM] N-Myc Gluc Gln Tet
1 SHEP-TR
without 
inducible 
N-Myc
2 2 / ↔ ↔ +
2 SHEP-TR-MYCN with inducible N-Myc 2 2 ↑ ↔ ↔ +
3 SHEP-TR-MYCN high Gluc, N-Myc low 4.5 2 ↓ ↑ ↔ −
4 SHEP-TR-MYCN low Gluc, N-Myc low 1 2 ↓ ↓ ↔ −
5 SHEP-TR-MYCN high Gln, N-Myc low 2 4 ↓ ↔ ↑ −
6 SHEP-TR-MYCN low Gln, N-Myc low 2 1 ↓ ↔ ↓ −
7 SHEP-TR-MYCN high Gluc, N-Myc high 4.5 2 ↑ ↑ ↔ +
8 SHEP-TR-MYCN low Gluc, N-Myc high 1 2 ↑ ↓ ↔ +
9 SHEP-TR-MYCN high Gln, N-Myc high 2 4 ↑ ↔ ↑ +
10 SHEP-TR-MYCN low Gln, N-Myc high 2 1 ↑ ↔ ↓ +
Table 1. Definition of groups for analyses of metabolite levels in SHEP-TR-MYCN cells with varying levels of 
carbon source supply as indicated (“Gluc”: glucose; “Gln”: glutamine). N-Myc expression in these cells, but not 
in SHEP-TR cells, can be induced by addition of tetracycline (“Tet”). Additionally, definition of carbon source 
concentrations as “high”, “low” or unchanged (indicated by a double arrow) is explained here.
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glutamine dependent in vitro, as they need glutamine-derived α-ketoglutarate to enter the TCA cycle, but are 
glutamine-independent in vivo due to fueling of the TCA cycle by glucose31. Expression of glutamine synthetase 
(GS) by cells of the tumor microenvironment might explain compensatory effects in cancer cells with reduced 
GS activity32. It has also been argued that routinely applied cell culture conditions will not appropriately mimic 
metabolic conditions found in human plasma33. Thus, experiments to model tumor cell responses to oncogenic 
activation in vitro have to be carefully designed. We here investigated the effects of ectopic MYCN expression 
in neuroblastoma cells lines in the presence of high or low supply with glucose or glutamine, respectively, as an 
approach to mimic both, oncogene-induced changes in metabolic patterns and response to altered carbon source 
supply. For metabolic profiling of these conditions, we chose SHEP neuroblastoma cells, in which we had previ-
ously noticed MYCN-induced HK2 upregulation indicating metabolic reprogramming16,27. Using a newly adapted 
system for inducible MYCN expression, designated SHEP-TR-MYCN, we were able to demonstrate that HKII 
induction by N-Myc was independent of carbon source supply (Fig. 1A). Moreover, N-Myc dependent upregula-
tion of HKII could be confirmed in other neuroblastoma cell lines (Fig. 2D). Metabolome analyses revealed that 
both, carbon source and N-Myc expression levels, cause significant and specific changes allowing for separation 
of these experimental groups by principal component analyses (Fig. 1B). Of note, we also observed significant 
interaction effects between N-Myc and carbon source levels (Fig. 1C,D) suggesting that N-Myc induced repro-
gramming also affects downstream metabolic processes under varying nutrient conditions. While our analy-
ses uncovered that N-Myc mediated regulation of metabolites affects all pathways investigated, classification of 
N-Myc regulated metabolites confirmed enrichment for metabolites within the categories “energy metabolism” 
Figure 2. (A) Comparison of aerobic respiration and glycolysis indicated by the oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) in SHEP-TR-MYCN cells with (“MYCN high”) and without 
induction of N-Myc (“MYCN low”). Colors indicate different glucose (Gluc) levels and N-Myc expression 
during cultivation and measurement; “MYCN low” cells are depicted in pink (1 g Gluc/l), light green (2 g Gluc/l) 
and light blue (4.5 g Gluc/l), while “MYCN high” cells are given in red (1 g Gluc/l), dark green (2 g Gluc/l) 
and dark blue (4.5 g Gluc/l). (B) Glycolysis and glycolytic capacity were monitored by measuring ECAR upon 
addition of external glucose and oligomycin in SHEP-TR-MYCN cells with and without induction of MYCN 
by tetracycline using cell numbers as indicated (“Norm. ECAR”: extracellular acidification rate normalized to 
10,000 cells). The color code indicates different cell numbers and MYCN status, as 104, 2 × 104 or 3 × 104 cells 
were used in the assay with and without induction of MYCN by tetracycline (“Tet”). Data were generated in 
triplicates in two independent experiments. Asterisks indicate a significance level p < 0.001. (C) SHEP-TR-
MYCN cells were cultivated in the absence (“MYCN low”) or presence of tetracycline (“MYCN high”) and 
incubated with 2-deoxyglucose. At time points indicated, cell viability was recorded. Color code identifies 
samples analyzed at 24 h in blue, at 48 hours in red, at 72 hours in green and at 96 hours in purple. Data were 
generated in triplicates in two independent experiments. (D) Hexokinase II (HKII) and N-Myc protein 
expression in SK-N-AS TR-MYCN, SY5Y TR-MYCN and SK-N-SH TR-MYCN cells. “+” and “−“ refer to 
addition of tetracycline (Tet), which is regulating MYCN expression levels. The information presented here is 
derived from two experiments as indicated by the separating vertical line.
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and a highly significant enrichment for metabolites involved in the glutathione pathway. We thus focused on 
analyses of two main pathways for energy harvest, glycolysis and glutamine metabolism, as the latter feeds also 
into glutathione biosynthesis. Indeed, we found a shift towards preferential use of glycolysis in MYCN-induced 
cells and an increased sensitivity towards glycolysis inhibition (Fig. 2). While this paper was in review, this was 
confirmed by results from Oliynyk et al. who showed that N-Myc increases the glycolytic and oxidative phos-
phorylation capacity of MYCN-amplified neuroblastoma cells. Moreover, they could demonstrate glutamine 
independence of mitochondrial respiration in MYCN-amplified neuroblastoma cells compared with non-MYCN 
amplified cells and that N-Myc high cells are especially vulnerable to inhibition of fatty acid oxidation34. We can 
conclude from these results that N-Myc reprograms neuroblastoma cells towards a highly energy producing 
and consuming phenotype. Glycolysis addiction in cancer cells with high levels of Myc has been described and 
linked to mTOR pathway activation35. Interestingly, we and others previously noticed an increased sensitivity of 
MYCN-dependent neuroblastoma towards mTOR inhibition27,36, suggesting that simultaneous blockade of glyc-
olysis and mTOR would be an option to interfere with both, metabolism and survival pathways.
The addiction of MYCN-amplified neuroblastoma cells to glutamine availability has been described14. A recent 
report indicated higher glutamate/glutamine ratios in neuroblastoma compared to other cell types37. These findings 
suggested that neuroblastoma can be categorized as a “glutamine-consuming” rather than a “glutamine-producing” 
tumor type. Of note, c-Myc regulates glutamine metabolism, at least in part, by repressing miR-23a and miR-23b 
resulting in enhanced expression of their target gene, glutaminase19. Recent reports pointed to a possible feedback 
mechanism, as MYC translation itself is regulated by intracellular levels of glutamine-derived adenosine nucleotides 
via a sequence element in the 3′-UTR of the MYC mRNA6. In our model cell lines, this effect cannot be analyzed in 
the absence of endogenous regulator elements in the 3′UTR of the MYCN encoding vectors. The emerging picture, 
however, is far from clear: blocking glutamine uptake and its metabolic conversion to α-ketoglutarate was well toler-
ated in all conditions analyzed, indicating compensatory mechanisms. Paradoxical effects were observed for CB-839, 
an inhibitor of mitochondrial glutaminase (GLS1) that is currently tested in early clinical trials for treatment of sev-
eral solid tumors multiple myeloma and acute myeloid leukemia38: while two of four neuroblastoma cell lines did not 
respond to CB-839, N-Myc expression combined with glutamine starvation enhanced metabolic activity of SK-N-SH 
and SHEP cells, however, this was not translating in increased cell proliferation (Supplemental Fig. 7). Viability of the 
Figure 3. (A–F) Cell viability depending on small-molecule inhibitors of glutamine metabolism in cell lines 
indicated. Grey triangles indicate cells incubated in the presence of low Gln with high (dark grey) or low 
(light grey) N-Myc levels; rectangles and circles depict cells cultivated in the presence of high Gln with high 
(rectangles) or low levels (circles) of N-Myc. In experimental conditions indicated, high MYCN expression was 
induced by addition of tetracycline (“+ Tet”). (G) Scheme depicting the biochemical steps, in which the small 
molecule inhibitors of glutamine metabolism are supposed to act (AOA: aminoxyacetate; DON: 6-diazo-5-oxo-
L-norleucine).
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latter two cell lines was not affected by DON, an irreversible glutamine-competitive inhibitor, at concentrations of up 
to 10 µM. However, limiting glutamine concentrations increased sensitivity towards DON in SY5Y and SKNAS cells, 
while N-Myc expression enhanced DON sensitivity 10-fold in SK-N-SH cells. Dissection of cellular responses on the 
level of the entire metabolome in SHEP cells revealed significant changes in glutathione-related metabolites upon var-
iation of glutamine availability, which affected the vast majority of intermediates on the route from glutamine to GSH 
(Fig. 4A,B). We thus hypothesized that glutamine addiction of N-Myc high cells could be attributed to an increased 
sensitivity towards ROS production. Increased demand for ROS detoxification has been recognized as a vulnerability 
of cancer cells in the past years. The concept has also helped to understand the mechanisms of action for cytotoxic 
drugs including As2O3 and anthracyclines, which are effective at least in part by glutathione oxidation and increased 
ROS production, respectively39. However, sensitivity of N-Myc high cells to inhibition of glutamine metabolism could 
not be rescued by external glutathione supply. Moreover, N-Myc high cells were not significantly more sensitive to the 
ROS-inducing agent, dimethyl fumarate, which was described to suppress neuroblastoma cell proliferation20. Thus, 
preferential killing of N-Myc high cells in the presence of glutamine metabolism inhibitors and limited glutamine sup-
ply cannot be explained by increased consumption of glutathione and increased ROS sensitivity.
As mentioned above, strategies aiming to limit carbon source availability of inhibition of primary metabolic 
pathways have to take into account not only plasticity of tumor cells themselves but also that other cell types in 
the tumor microenvironment could serve as a carbon source in vivo32. Our data consistently show that responses 
to interference with primary metabolism are cell-type specific and that these cell-type specific differences largely 
contribute to metabolic plasticity reflecting inherent heterogeneity of our cell models. However, our results con-
firm interference with glucose and glutamine availability are possible avenues for exploiting metabolic depend-
encies of N-Myc high cells, which have to be further explored in in vivo models.
Received: 30 October 2018; Accepted: 9 April 2020;
Published: xx xx xxxx
Figure 4. (A) Data presented in Fig. 1D were re-analyzed to visualize a significant N-Myc-mediated effect 
on glutathione (GSH) metabolism. In total, 32 out of 34 GSH-related metabolites are significantly affected by 
N-Myc levels according to ANOVA. (B) Main routes of the glutathione pathway (modified from30). Metabolites 
which are significantly affected by N-Myc for the sample groups under constant glucose and varying glutamine 
concentration in the medium are marked by red boxes. Interestingly, all significantly altered species are found to 
be decreased upon MYCN induction. Metabolites that have not been detected by UPLC are greyed (AA: amino 
acid, BCKA: branched chain keto acids, F-6-P: fructose-6-phosphate, GSSG: glutathione disulfide, LOOH: 
lipid hydroxyperoxide, LOH: lipid peroxyl radical, NA-cysteine: N-acetyl-cysteine, OTC: oxothiazolidine-4-
carboxylate, R-5-P: ribose-5-phosphate, R, R*: radicals, X: xenobiotic). (C,D) Redox modulation by addition 
of GSH (100 mM) in the presence of varying concentrations of DON (C) or the ROS-inducer mono-methyl 
fumarate (MMF, D) in SHEP-TR-MYCN cells with or without induction of MYCN expression (“+Tet” and “−
Tet”, respectively).
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